Clinitech Laboratory Share Price
35.10+0.00 (+0.00%)
-21.65% past 1 Year
Corporate filings & documents
Announcements
We are enclosing herewith copy of newspaper advertisement w.r.t Notice and e-voting for Annual General Meeting to be held on Thursday September 24 2026 at 11.30 A.M through video conferening in following newspaper:English Daily - Financial ExpressMarathi Daily - Vritamanas
3 weeks agoWe are enclosing herewith copy of newspaper advertisement w.r.t Notice and e-voting for Annual General Meeting to be held on Thursday September 24 2026 at 11.30 A.M through video conferening in following newspaper:English Daily - Financial ExpressMarathi Daily - Vritamanas
3 weeks agoNotice of Annual General Meeting along with all annexures to be held on September 24 2026 at 11.30 A.M (IST) through video conferencing.
4 weeks agoNotice of Annual General Meeting along with all annexures to be held on September 24 2026 at 11.30 A.M (IST) through video conferencing.
4 weeks agoDate of 16th AGM: September 24 2026Book Closure Dates: September 18 2026 to September 24 2026 (both days inclusive).
4 weeks agoDate of 16th AGM: September 24 2026Book Closure Dates: September 18 2026 to September 24 2026 (both days inclusive).
4 weeks agoAnnual Report for thr FY 2025-26 along with Notice of AGM and all annexures thereto
4 weeks agoAnnual Report for thr FY 2025-26 along with Notice of AGM and all annexures thereto
4 weeks agoWe hereby inform that the Board of Directors of the company at its meeting held today i.e. August 17 2026 for which intimation was already given have: Approved appointment of director retiring by rotation; Approved the Boards report of the company along with all annexures thereof for the FY 2025-26; Approved notice convening 16th Annual General Meeting and the date time & venue thereof; Finalized the dates of Book Closure for the purpose of forthcoming 16th Annual General Meeting; Finalized the appointment of Mr. Deep Shukla Practising Company Secretary as the scrutinizer to oversee the voting process in a fair and transparent manner;
1 month agoWe hereby inform that the Board of Directors of the company at its meeting held today i.e. August 17 2026 for which intimation was already given have: Approved appointment of director retiring by rotation; Approved the Boards report of the company along with all annexures thereof for the FY 2025-26; Approved notice convening 16th Annual General Meeting and the date time & venue thereof; Finalized the dates of Book Closure for the purpose of forthcoming 16th Annual General Meeting; Finalized the appointment of Mr. Deep Shukla Practising Company Secretary as the scrutinizer to oversee the voting process in a fair and transparent manner;
1 month agoClinitech Laboratory Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 inter alia to consider and approve 1. To consider and approve appointment of director retiring by rotation;2. To approve the Boards report of the company along with all annexures thereof for the FY 2025-26;3. To consider and approve notice convening 16th Annual General Meeting and the date time & venue thereof along with finalization of book closure dates;4. To finalize the appointment of Mr. Deep Shukla Practising Company Secretary as the scrutinizer to oversee the voting process in a fair and transparent manner;5. Any other matter with the permission of the Chair.
1 month agoClinitech Laboratory Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/08/2026 inter alia to consider and approve 1. To consider and approve appointment of director retiring by rotation;2. To approve the Boards report of the company along with all annexures thereof for the FY 2025-26;3. To consider and approve notice convening 16th Annual General Meeting and the date time & venue thereof along with finalization of book closure dates;4. To finalize the appointment of Mr. Deep Shukla Practising Company Secretary as the scrutinizer to oversee the voting process in a fair and transparent manner;5. Any other matter with the permission of the Chair.
1 month agoDisclosure under REg 74(5) of SEBI (DP) Regulations for the quarter ended June 30 2026
2 months agoDisclosure under REg 74(5) of SEBI (DP) Regulations for the quarter ended June 30 2026
2 months agoStatement disclosing no deviation and Variation from object of issue as on March 31 2026
3 months agoOutcome of Board meeting held today i.e May 28 2026 through video conferencing at 02.30 P.M for approval of Audited Financial Results for the half year and financial year ended March 31 2026
3 months agoWith reference to the above captioned subject we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today i.e. on May 28 2026 for which intimation was already given to you the Board of Directors has: 1. considered and approved the Audited Standalone & Consolidated Financial Results of the Company along with Auditors Report for the half year and financial year ended March 31 2026;2. taken note of Internal Audit Report for the half year ended March 31 2026;3. taken note of related party transactions during the year ended March 31 2026 and approved the estimated related party transactions to be held for FY 2026-27.
3 months agoClinitech Laboratory Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 inter alia to consider and approve To consider and approve the Audited Standalone & Consolidated Financial Statements & Financial Results of the Company along with Auditors Report for the half year and financial year ended March 31 2026; To take a note of internal audit report for the year ended March 31 2026; To consider and note the related party transactions during the year ended March 31 2026; Any other matter with the permission of the Chair.
4 months agoClinitech Laboratory Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 inter alia to consider and approve To consider and approve the Audited Standalone & Consolidated Financial Statements & Financial Results of the Company along with Auditors Report for the half year and financial year ended March 31 2026; To take a note of internal audit report for the year ended March 31 2026; To consider and note the related party transactions during the year ended March 31 2026; Any other matter with the permission of the Chair.
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Clinitech Laboratory Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85195MH2010PLC201078</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.36</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Shruti Patankar <br/> Designation: Company Secretary <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Rahul Patil <br/> Designation: CFO <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 27/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoThis is to inform that the company has entered into Memorandum Of Understanding ("MOU") dated 25th April 2026 with M/s. MD Plus Multispeciality Clinic
4 months agoThis is to inform that the company has entered into Memorandum Of Understanding ("MOU") dated 25th April 2026 with M/s. MD Plus Multispeciality Clinic
4 months agoUndertaking for non-applicability of disclosure under Reg 23 of SEBI (LODR) Regulations 2015 w.r.t related party transaction.
5 months agoUndertaking for non-applicablity of Annual Secretarial compliance report under Reg 24A of SEBI (LODR) since our company is SME listed entity.
5 months agoGeneral update under Reg 30 of SEBI (LODR) Regulations for change in market maker from SVCM Securities Private Limited to Kalpalabdhi Financials Private Limited w.e.f April 10 2026 as approved by Board through circular resolution passed on April 09 2026.
5 months agoGeneral update under Reg 30 of SEBI (LODR) Regulations for change in market maker from SVCM Securities Private Limited to Kalpalabdhi Financials Private Limited w.e.f April 10 2026 as approved by Board through circular resolution passed on April 09 2026.
5 months agoCertificate under REg 74(5) of SEBI (DP) Regulations for the quarter ended March 31 2026.
5 months agoCertificate under REg 74(5) of SEBI (DP) Regulations for the quarter ended March 31 2026.
5 months agoGeneral Update w.r.t to receipt of letter from promoter under Reg 31(4) of SEBI SAST regulations for the yera ended March 31 2026
5 months agoGeneral Update w.r.t to receipt of letter from promoter under Reg 31(4) of SEBI SAST regulations for the yera ended March 31 2026
5 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Nayak & PACs
5 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Nayak & PACs
5 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Siddhesh Nayak & PACs
5 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Umakant Nayak & PACs
5 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Umakant Nayak & PACs
5 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Siddhesh Anant Nayak & PACs
5 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Siddhesh Anant Nayak & PACs
5 months agoClosure of Trading Window for Insiders of the company from Wednesday April 01 2026 for Audited Financial Results for the half year and year ended March 31 2026. The Trading window will open 48 hours after declaration of the said financial results.
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Umakant Nayak & PACs
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Umakant Nayak & PACs
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Umakant Nayak & PACs
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Umakant Nayak & PACs
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Umakant Nayak
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Umakant Nayak
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Umakant Nayak
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Umakant Nayak
6 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Jagdish Umakant Nayak
6 months agoDisclosure under Regulation 30 of SEBI (LODR) Regulations 2015 w.r.t Incorporation of Subsidiary of the company
7 months agoDisclosure under Regulation 30 of SEBI (LODR) Regulations 2015 w.r.t Incorporation of Subsidiary of the company
7 months agoWe hereby inform that the Board of Directors of the company at its meeting held today i.e. February 06 2026 held at registered office without intimation have: Approved formation of Subsidiary in the name & style as Analog IVD Solutions Private Limited and subscribe the memorandum; Approved availment of Term loan of INR 22.50 Lakhs from Bank of Baroda.
7 months agoAnnual reports
Concalls & investor presentations
No presentations found